The HOME Study (HPN With OMEGA-3)

Inclusion: * Signed informed consent available * Male or female patients ≥ 18 years of age * Patients with chronic intestinal failure receiving HPN including lipids in whom the parenteral macronutrients have not been changed by more than 10% for at least 3 months * Patients receiving ≥ 3.0 g lipids/kg body weight per week Exclusion: * Persistent high total bilirubin values in medical history of last 6 months (\> 40µmol/l) * Patients in whom PN was interrupted for longer than 4 continuous weeks in the preceding 6 months * Patients with history of cancer and anti-cancer treatment within the last 2 years * Hypersensitivity to egg, fish, peanut or soya-bean protein or to any of the active substances or excipients * Patients treated in the past or currently with Teduglutide * Contraindications to investigational products (if available from medical records) including: * Severe hyperlipidemia, including severe hypertriglyceridaemia (≥1000 mg/dl or 11.4 mmol/l) * Severe coagulopathy * Intrahepatic cholestasis * Severe hepatic insufficiency * Severe renal insufficiency in absence of renal replacement therapy * Acute thromboembolic events * Fat embolism * Aggravating haemorrhagic diatheses * Metabolic acidosis * General contraindications to parenteral nutrition (if available from medical records) including: * Unstable circulatory status with vital threat (states of collapse and shock) * Acute phase of cardiac infarction or stroke * Unstable metabolic condit…